GALDERMA

Relfydess: consistent efficacy across patient profiles and new insights into real-world value
Galderma will share new economic modelling data, reflecting realworld experience of Relfydess from aesthetic clinics across multiple markets.1The analysis shows that switching from traditional powder toxins to Relfydess’ readytouse formulation could generate an annual profit increase, driven by faster onset, longer duration, higher patient satisfaction and therefore increased capacity for new appointments.1

Data demonstrating Relfydess’ equally strong efficacy in both toxinnaïve and previously treated patients will also be shared, showing high response rates, rapid onset from Day 1 and sustained improvements through six months.2Galderma will also present expertled consensus recommendations that address key unmet needs in realworld clinical practice, offering clear, practical guidance for optimal dosing, injection patterns and treatment plannin
=*=*=*=*=*=
当前为第3/20页
下一页-上一页-
=*=*=*=*=*=
返回新闻列表
返回网站首页